Although many studies have demonstrated the positive effects of using PD-1 inhibitors as a targeted therapy in oesophageal cancer, the mixed results have demonstrated the need to be able to stratify patients in order to identify those that have a better chance of responding to their treatment. The gene discussed is PDCD1; the disease is carcinoma of esophagus.